Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD

Nephrology Dialysis Transplantation

Volumn 26, Issue 4, 2011, Pages 1117-1119

  Olgaard, Klaus ^a   Lewin, Ewa ^a   Silver, Justin ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCIMIMETIC AGENT; CALCITRIOL DERIVATIVE; CALCIUM SENSING RECEPTOR; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; STEROL; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX1; VITAMIN D;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; HUMAN; MINERAL BONE DISORDER; MUSCLE CELL; NONHUMAN; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; VASCULAR SMOOTH MUSCLE;

BONE DISEASES, METABOLIC; CALCINOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PROGNOSIS; RENAL DIALYSIS; VITAMIN D; VITAMINS;

EID: 79953853312     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq862     Document Type: Article

References (24)

1. Moe SM. Definition and classification of renal osteodystrophy and chronic kidney disease-mineral bone disorder (CKD-MBD). In: K Olgaard, IB Salusky, J Silver (eds). The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford: Oxford University Press, 2010; 1-14
2. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980
3. Shroff RC, Shanahan CM. Pathogenesis of vascular calcification: experimental studies. In: K Olgaard, IB Salusky, J Silver (eds). The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford: Oxford University Press, 2010; 283-301
4. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897
5. Jono S, Nishizawa Y, Shioi A et al. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98: 1302-1306 (Pubitemid 28443394)
6. Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519
7. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464
8. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715 (Pubitemid 47373790)
9. Lopez I, Mendoza FJ, guilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307
10. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with cal-citriol. J Am Soc Nephrol 2006; 17: 795-804
11. Smajilovic S, Hansen JL, Christoffersen TE et al. Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 2006; 348: 1215-1223 (Pubitemid 44308418)
12. Joki N, Nikolov IG, Caudrillier A et al. Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. Bone 2009; 45Suppl 1S30-S34
13. Kawata T, Nagano N, Obi M et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008; 74: 1270-1277
14. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51 (Pubitemid 27494749)
15. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calci-ficationin chronic kidney disease.JAmSoc Nephrol 2011; 22: 124-136
16. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392 (Pubitemid 29353135)
17. Masuda H, Chikuda H, Suga T et al. Regulation of multiple ageinglike phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev 2005; 126: 1274-1283 (Pubitemid 41572244)
18. Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008; 19: 1092-1105
19. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
20. Raggi P, Chertow GM, Urena P et al. The ADVANCE Study: a randomized study to evaluate the effects of cinacalcet plus low dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2010
21. Jean G, Terrat JC, Vanel Tet al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemo-dialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
22. Gutierrez OM, Mannstadt M, Isakova Tet al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
23. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: F882-F889
24. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315 (Pubitemid 43673410)